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Although trastuzumab, a recombinant humanized anti-ErbB2 antibody, is widely used in the 
treatment of breast cancer, neither its mechanism of action, nor the factors leading to 
resistance are fully understood. We have previously shown that antibody-dependent cellular 
cytotoxicity is pivotal in the in vivo effect of trastuzumab against JIMT-1, a cell line showing 
in vitro resistance to the antibody, and suggested that masking of the trastuzumab-binding 
epitope by MUC-4, a cell surface mucin, took place. Here, we further explored the role of 
masking of ErbB2 in connection with CD44 expression and synthesis of its ligand, 
hyaluronan. We show that high expression of CD44 observed in JIMT-1 cells correlates with 
ErbB2 downregulation in vivo, while siRNA-mediated inhibition of CD44 expression leads to 
decreased rate of trastuzumab internalization and low cell proliferation in vitro. An inhibitor 
of hyaluronan synthesis, 4-methylumbelliferon (4-MU) significantly reduced the hyaluronan 
level of JIMT-1 cells both in vivo and in vitro leading to enhanced binding of trastuzumab to 
ErbB2 and increased ErbB2 down-regulation. Furthermore, the inhibitory effect of 
trastuzumab on the growth of JIMT-1 xenografts was significantly increased by 4-MU 
treatment. Our results point to the importance of the CD44-hyaluronan pathway in the escape 
of tumour cells from receptor-oriented therapy. 
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Introduction 
Overexpression of ErbB2 has been unquestionably linked to adverse prognosis in breast 
cancer.1 ErbB2 heterodimerizes with other members of the ErbB family of receptor tyrosine 
kinases (RTK) leading to enhanced ligand binding affinity, protection from lysosomal 
degradation and diversified signaling.2 ErbB2 is viewed as an non-autonomous, ligand-less, 
positive regulator of ErbB signaling,2 but its participation in non-ErbB protein-mediated 
signaling is attracting more and more interest as well. Among these, β-integrins,3 MUC-44 
and CD445 are probably the best known candidates whose roles in cancer progression are 
well documented.3,6,7 ErbB2 is embedded into this network of signaling and accessory 
molecules and by its promiscuous association profile it promotes cancer progression.8 
CD44 is recognized as the major hyaluronan receptor having several, alternatively spliced 
isoforms varying in their physiological function.9 Binding of hyaluronan activates CD44-
mediated signal transduction pathways via interactions between CD44, Grb2, Vav2 and 
ErbB2.10 CD44 is involved in the direct regulation of ErbB211 and multiple other RTKs.12 It 
has been suggested that ligation of CD44 by endogenous hyaluronan leads to the activation of 
the phosphatidylinositol 3-kinase (PI3K)-Akt survival pathway,13 and that displacement of 
endogenous hyaluronan by exogenous hyaluronan oligosaccharides disrupts the activation.12 
CD44-mediated cytoskeletal rearrangements have been observed6 implying the involvement 
of CD44 in cellular adhesion, migration and invasion.14 CD44 is almost absent in normal 
human breast epithelial cells, emerges in benign and premalignant lesions, and is upregulated 
in carcinomas.15 However, a recent study suggested that CD44 opposes rather than promotes 
the spreading of breast carcinoma in mice.16 
While the role of CD44 in breast cancer progression in vivo is not completely settled, the 
accumulation of hyaluronan around malignant cells or in adjacent stroma has been 
unambiguously shown to be an indicator of poor prognosis in breast cancer.17 In line with the 
findings on human tumours, hyaluronan synthesis facilitates the invasive growth of grafted 
tumour cells in vivo,18 and blocking hyaluronan interactions with its receptors, using soluble 
CD44 or hyaluronan oligomers, inhibits tumour cell growth in experimental animals.19 
Besides creating signals to prevent apoptosis 13, hyaluronan is required for activation of the 
ErbB2-ErbB3 receptor leading to the formation of cardiac valves.20 Thus, there is mounting 
evidence that ErbB2, CD44 and hyaluronan are connected both in physiological signaling as 
well as cancer pathogenesis through mechanisms largely unknown at present.5,11 
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Being a membrane protein and a key member of survival and proliferation signaling 
pathways ErbB2 is the target of receptor-oriented antibody therapy.21 Trastuzumab 
(Herceptin), a humanized monoclonal anti-ErbB2 antibody, induces objective clinical 
responses in 40% of patients as a single agent given as first-line treatment of ErbB2-
overexpressing metastatic breast cancer.22 Although combination of trastuzumab with 
conventional chemotherapy increases response rates dramatically, the development of 
resistance seems currently inevitable.23 Direct action of trastuzumab on ErbB2 (e.g. ErbB2 
down-regulation, inactivation of Akt, inhibition of metalloprotease-mediated shedding)24 and 
antibody-dependent cellular cytotoxicity (ADCC)25,26 have been invoked to explain the 
mechanism of action of trastuzumab. Despite intense investigations trastuzumab resistance 
remains enigmatic and unpredictable in the clinical setting. Production of EGF-like growth 
factors,27 loss of PTEN,28 masking of ErbB24 and impaired ADCC reaction29 have all been 
suggested as possible mechanisms.  
In the current paper we investigated JIMT-1, a cell line showing in vitro resistance to 
trastuzumab,30 and found a high level of CD44 overexpression. We showed previously that 
the in vivo trastuzumab resistance of the cell line is partial, and development of complete 
trastuzumab resistance takes 5-10 weeks.26 We suggested that masking of ErbB2 may be the 
culprit.4 Given the suggested association of CD44 with ErbB211 we asked whether CD44 
plays any significant role in the survival of JIMT-1 during trastuzumab therapy. Using 
siRNA-mediated suppression of CD44 expression we showed that CD44 is necessary for 
trastuzumab-induced internalization of ErbB2 and for the survival of JIMT-1 cells in vitro. 4-
methylumbelliferone (4-MU), a hyaluronan synthase inhibitor, has been shown to increase 
the efficiency of chemotherapy.31 We reasoned that hyaluronan may play a role in masking of 
cell surface ErbB2.32 We show that in vitro and in vivo treatment with 4-MU decreased the 
pericellular hyaluronan concentration in JIMT-1 xenografts accompanied by increased 
binding of trastuzumab to ErbB2. 4-MU acted synergistically with trastuzumab in inhibiting 
the progression of JIMT-1 tumours. Elucidation of the role of CD44 overexpression in 
trastuzumab resistant cell lines may help understand the causes of therapeutic failures in 
patients with this type of breast cancer. 
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Materials and Methods 
Cells. JIMT-1 cells were grown in F-12/ DMEM (1:1) supplemented with 10% FCS, 60 
units/L insulin and antibiotics.30 The SKBR-3 cell line was obtained from the American Type 
Culture Collection (Rockville, MD) and grown according to its specifications. 
Antibodies.  Trastuzumab (Herceptin) was purchased from Roche Ltd. (Budapest, Hungary). 
Mab 2C4 was a generous gift from Genentech (South San Francisco, CA). Monoclonal 
antibodies against ErbB2 (ErbB2-76.5) and CD44 (Hermes-3) were produced from their 
hybridoma supernatants (ErbB2-76.5 obtained from Y. Yarden, Weizmann Institute of 
Science, Rehovot, Israel; Hermes-3 produced by the HB-9480 hybrodima obtained from 
ATCC) and purified using protein A affinity chromatography. Hermes-3 was kindly donated 
by Dr. Sirpa Jalkanen (University of Turku, Finland). Cy3- and Cy5-conjugated goat anti 
human IgG (H+L) Fab was obtained from Jackson ImmunoResearch Europe 
(Cambridgeshire, UK). Conjugation of primary antibodies with AlexaFluor (Molecular 
Probes, Eugene, OR), Cy3 and Cy5 (Amersham, Braunschweig, Germany) dyes was carried 
out according to the manufacturers’ specifications. 
Hyaluronan. Highly purified large molecular weight hyaluronan (HA-LMW) with an 
average molecular mass of 1.2×106 Da was donated by Genzyme (Cambridge, MA). Purified 
hyaluronan decasaccharides (HA10) were kindly provided by Seikagaku Corporation (Tokio, 
Japan).  
Western blotting. Whole cell lysates were prepared in lysis buffer  containing 20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 % Triton X-100, 1 Complete 
Mini (Roche, Mannheim, Germany) protease inhibitor cocktail tablet/10 mL, 1 mM Na3VO4, 
1 mM PMSF, 10 mM NaF, 10 mM β-glycerol phosphate and 10 mM Na4P2O7. 
Immunoprecipitation of ErbB2 and ErbB1 were carried out with Ab3-OP15 antibody 
(Calbiochem-Merck Biosciences, Schwalbach, Germany) and F4 (E3138, Sigma, 
Schnelldorf, Germany), respectively, for 1 h on ice and Sepharose 4B Fast Flow Protein G 
beads (Sigma). Immunoprecipitates were resolved on SDS-polyacrylamide gels and blotted to 
nitrocellulose membranes. The following antibodies were used for primary labelling of the 
membranes at dilutions suggested by the manufacturers: Ab3-OP15 for ErbB2, F4 for ErbB1, 
PY99-sc7020 (Santa Cruz Biotechnology, Santa Cruz, CA) for phosphotyrosine and Hermes-
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3 for CD44. Peroxidase-conjugated goat anti-mouse IgG and an enhanced 
chemiluminescence kit (Amersham, Freiburg, Germany) were used for detection. 
Flow cytometric measurement of cell numbers and receptor expression levels. 
Quantitative determination of receptor expression levels was carried out on a FACSCalibur 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ) using Qifikit (DakoCytomation, 
Glostrup, Denmark) according to the manufacturer’s instructions. In proliferation assays cells 
were counted with a FacsArray flow cytometer (Becton Dickinson). 
Xenograft tumours. The severe combined immunodeficiency (SCID) C.B-17 scid/scid 
mouse population originated from the laboratory of Fox Chase Cancer Center, Philadelphia, 
PA, and were housed in a pathogen-free environment. Only nonleaky mice with murine IgG 
levels below 100 ng/ml were used in this study. Seven-week old female SCID mice were 
given a single subcutaneous injection of 5×106 JIMT-1 cells suspended in 150 μl Hank’s 
buffer and mixed with an equal volume of Matrigel (Basement Membrane Matrigel, BD 
Biosciences, Bedford, MA). Tumour volumes were calculated as the product of the length, 
width and height of the tumour measured once a week with a caliper. Trastuzumab was 
administered at a dose of 5 μg/g by weekly intraperitoneal (i.p.) injection. Control mice 
received weekly i.p. injection of 100 µl physiologic saline. Animals were euthanized by CO2 
inhalation. The experiments were done with the approval of the ethical committee of the 
University of Debrecen. 
4-methylumbelliferone treatment. 4-methylumbelliferone (4-MU) (Sigma, Budapest, 
Hungary), an inhibitor of hyaluronan synthase, was suspended in 1% arabic gum and 
administered orally at a dose of 3 mg/g body weight twice daily.33 For in vitro experiments 4-
MU was dissolved in PBS and added to the culture medium at a concentration of 1 mM. 
Immunohistochemistry. Subcutaneous tumours were removed from anesthetized mice, 
covered with Shandon Cryomatrix (Thermo Electron Corporation, Waltham, MA) and stored 
in liquid nitrogen. 20-µm thick fast frozen samples were made by Shandon AS-620E 
Cryotome (Thermo Electron Corporation) on silanized slides, fixed in 4% formaldehyde for 
30 min, and washed twice in PBS (pH 7.4) supplemented with 1% BSA for 20 min at room 
temperature. The slides were labeled with a saturating concentration (10-20 µg/ml) of 
fluorophore-conjugated antibodies in 100 µl PBS containing 1% BSA (PBS-BSA) overnight 
on ice. The samples were washed twice with PBS-BSA and covered with 15 µl Mowiol 
(Merck, Budapest, Hungary). For labelling of hyaluronan tissue sections were treated with  
endogenous biotin blocking kit (Molecular Probes) followed by labelling with 5 μg/ml 
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biotinylated HABC (hyaluronan binding complex) at 4 oC overnight.34 Prior to staining with 
fluorescein-avidin the samples were washed five times in PBS-BSA. 
Confocal microscopy. A Zeiss LSM 510 confocal laser-scanning microscope (Carl Zeiss 
AG, Göttingen, Germany) was used to image samples.  AlexaFluor488 was excited at 488 nm 
and detected between 505-530 nm. Cy3 and AlexaFluor546 were excited with the 543 nm 
line of a green He-Ne laser, and emission was measured between 560-615 nm. Cy5 and 
AlexaFluor647 were excited with the 633 nm line of a red He-Ne laser, and their emissions 
were measured over 650 nm. Fluorescence images were taken as 1-μm optical sections using a 
63x (NA=1.4) oil immersion objective. 
Image analysis. Confocal microscopic images were analyzed with the DipImage toolbox (Delft 
University of Technology, Delft, The Netherlands) under Matlab (Mathworks Inc., Natick, MA). 
The cell membrane was identified by a manually-seeded watershed algorithm35 using a custom-
written interactive algorithm implemented in Dipimage/Matlab. The fluorescence intensity was 
evaluated only in pixels corresponding to the cell membrane. For the analysis of the influence of 
CD44 expression on the relative binding of trastuzumab to ErbB2 tissue sections were triple-
labeled with AlexaFluor488-ErbB2-76.5, Cy3-anti-human IgG (to visualize trastuzumab) and 
AlexaFluor647-Hermes-3 (against CD44). A two-dimensional histogram (dot plot) of 
trastuzumab vs. ErbB2 intensity was prepared using only membrane pixels. The CD44 
expression level was separately evaluated in pixels corresponding to high trastuzumab/ErbB2 
and low trastuzumab/ErbB2 ratios identified based on the dot plot. 
Colocalization between two different fluorescent labels was calculated according to Pearson’s 
formula: 
( )( )














where Ik and Jk are the intensities of the kth pixel in the first and second image, respectively, 
Imean and Jmean are the average fluorescence intensities of the first and second image, 
respectively. Low intensity pixels were excluded from the analysis. The value of the cross-
correlation coefficient ranges from +1 to −1. Values close to 1, 0 and −1 indicate high and 
low degree of colocalization, and anticorrelation, respectively. Colocalization was evaluated 
using a custom-made software written in LabView (National Instruments, Austin, TX). 
Fluorescence resonance energy transfer (FRET). Flow cytometric FRET measurements 
were performed on a FACSVantage SE instrument with DiVa option (Becton Dickinson) 
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equipped with three lasers emitting at 488, 532 and 633 nm. A detailed description of the 
method has been published elsewhere.36 Cellular autofluorescence was measured in the FL1 
channel (excited by the 488 nm laser) through a 530/30 nm band pass filter to discard debris 
and dead cells. Donor fluorescence was excited at 532 nm and recorded in the FL4 channel 
through a 585/42 nm bandpass filter, while the acceptor was excited at 633 nm and detected 
in the FL6 channel through a 650 nm long pass filter. The FRET intensity was excited at 532 
nm and detected in the FL5 channel through a 650 nm long pass filter. Calculations were 
carried out on a cell-by-cell basis using the ReFlex software.37 FRET efficiencies were 
normalized to a 1:1 donor-acceptor ratio38 and are presented as mean values of FRET 
histograms of 10,000 cells. 
Internalization of trastuzumab. siRNA-transfected and control cells were incubated with 20 
µg/ml AlexaFluor647-labeled trastuzumab at 37°C. The samples were treated with acid strip 
buffer (0.5 M NaCl, 0.1 M glycine, pH 2.5) for 3 minutes on ice followed by washing and 
resuspension in PBS. Cells were analyzed by flow cytometry, and the internalized fraction of 
trastuzumab was calculated by dividing the mean fluorescence intensity of the acid-stripped 
sample with that of the non-acid-treated control. 
RNA interference (RNAi). Small interfering RNA (siRNA) against human CD44 were 
designed and synthesized by Dharmacon (Chicago, IL) using the SMARTselection rules. The 
sequences of the anti-sense strands of the siRNAs are:  AUGUCUUCAGGAUUCGUUCUU 
(CD44 siRNA-4), UAUUCAAAUCGAUCUG CGCUU (CD44 siRNA-5). An siRNA against 
GFP was used as a negative control.39 siRNA transfection of JIMT-1 was carried out with the 
Nucleofector device of Amaxa (Cologne, Germany) according to the manufacturer’s 
specifications. The optimal electroporation conditions (solution V, program T-20) were 
selected using GFP plasmid transfection.
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Results 
CD44 is overexpressed on trastuzumab resistant JIMT-1 cells and associated with 
ErbB2. We compared the expression levels of CD44 in trastuzumab resistant and sensitive 
breast cancer cell lines in order to reveal the possible roles of CD44 in trastuzumab 
resistance. Flow cytometric data showed a ~35-times higher expression level of CD44 in 
trastuzumab resistant JIMT-1 cells (2.3±0.3 million/cell) than in SKBR-3 (65000±5000/cell), 
their trastuzumab-sensitive counterpart (Fig.1A). Since CD44 has been shown to interact with 
ErbB2 in ovarian cancer,5,10 we investigated the potential interaction between them. Analysis 
of confocal microscopic images yielded cross-correlation coefficients of 0.612 and 0.602 
between CD44 and ErbB2 on JIMT-1 and SKBR-3 cells, respectively (Fig.1B,C). The cross-
correlation coefficient between two different antibodies against ErbB2 was used as a positive 
control. The fact that the cross-correlation coefficient of the positive control was not 
substantially different from that between CD44 and ErbB2 implies a strong colocalization 
between these molecules on the micrometer scale. Normalized flow cytometric fluorescence 
resonance energy transfer (FRET) values of 16±3% and 10±3% for the association of CD44 
and ErbB2 in JIMT-1 and SKBR-3, respectively, show that these molecules are associated at 
the molecular level as well (Fig.1B), since FRET values above 5% are considered to imply 
significant association.40 The above biophysical data demonstrating association between 
ErbB2 and CD44 in JIMT-1 cells were reinforced by molecular biological methods. ErbB2 
co-immunoprecipitated with CD44 (Fig. 1D, left panel), and its tyrosine phosphorylation was 
increased by large molecular weight hyaluronan, whereas hyaluronan decasaccharide 
inhibited ErbB2 tyrosine phosphorylation (Fig. 1D, middle panel). Neither slow, nor large 
molecular weight hyaluronan modified the activation state of ErbB1 (Fig. 1D, right panel). 
CD44 expression correlates with trastuzumab internalization in JIMT-1 xenografts. In 
order to study the possible role of CD44 overexpression in trastuzumab resistance seven-
week old female SCID mice were inoculated by JIMT-1 cells with a single subcutaneous 
injection. Mice received trastuzumab or physiologic saline weekly starting immediately after 
tumour injection.  Mice were treated with trastuzumab for 9 weeks, then by physiologic 
saline for another 6 weeks before sacrificing. Tumour sections were triple-stained against 
ErbB2, trastuzumab and CD44. The watershed algorithm was used to segment the images. 
The seeds for the watershed algorithm were placed inside cells positive for CD44 and ErbB2. 
Since mouse stromal cells express neither CD44 nor ErbB2, this approach ensured that the 
analysis was restricted to JIMT-1 cells. We observed a lack of tight correlation between 
trastuzumab binding and ErbB2 expression in these mice whose trastuzumab therapy had 
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been suspended for 6 weeks (Fig. 2B,D). The trastuzumab/ErbB2 ratio was inversely 
correlated with CD44 expression, i.e. cells in which the relative binding of trastuzumab to 
ErbB2 was low displayed high CD44 expression (Fig. 2D,E). The lack of strict correlation 
between trastuzumab binding and ErbB2 expression could be caused by local heterogeneities 
in trastuzumab binding or internalization. We excluded the role of trastuzumab binding by 
investigating tumour sections from mice sacrificed immediately after 15 weeks of 
trastuzumab treatment and showing a tight correlation between trastuzumab binding and 
ErbB2 expression (Fig. 2F). Unfortunately, direct quantitation of trastuzumab internalization 
by measuring fluorescence intensity inside cells was not possible due to the low signal-to-
noise ratio. Therefore, we used an alternative approach by analyzing the correlation between 
CD44 and ErbB2 expressions before, during and after trastuzumab treatment, and found that 
they show a positive correlation in control mice (Fig. 2G) and in mice in which trastuzumab 
treatment has been stopped (Fig. 2I). Strikingly, CD44 and ErbB2 expression levels were 
inversely correlated with each other during trastuzumab treatment (Fig. 2H), i.e. pixels with 
high CD44 expression displayed low ErbB2 intensity and vica versa. This finding can be 
rationalized by assuming that ErbB2 is internalized and down-regulated more efficiently in 
cells with high CD44 expression. 
RNA interference (RNAi)-mediated suppression of CD44 expression inhibits 
trastuzumab internalization. The in vivo results supporting the role of CD44 in 
trastuzumab-mediated ErbB2 internalization were tested by in vitro RNAi experiments. Two 
siRNAs against CD44 elicited efficient and specific inhibition of CD44 expression in JIMT-1 
supported by the lack of effect of an irrelevant siRNA on CD44 expression, and the lack of 
CD44 siRNA-induced suppression of the expression of an irrelevant protein (Fig. 3A). 
Quantitative flow cytometric analysis confirmed that CD44 siRNAs inhibited trastuzumab 
internalization by ~50% (Fig. 3B). 
4-methylumbelliferone (4-MU) synergizes with trastuzumab in inhibiting the growth of 
JIMT-1 xenografts. We showed that CD44 plays a role in trastuzumab internalization both 
in vivo and in vitro. However, the contribution of trastuzumab-mediated ErbB2 
internalization to the mechanism of action of the antibody has been repeatedly questioned 
41,42. Therefore, we directly tested whether the CD44-hyaluronan pathway can influence the 
therapeutic efficacy of trastuzumab. Mice injected with JIMT-1 xenografts were treated with 
4-MU (an inhibitor of hyaluronan synthase33) or trastuzumab, or both starting immediately 
after tumour inoculation. Each treatment group contained eight animals. The fact that 
trastuzumab treatment was started the same day as tumour injection made JIMT-1 cells 
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(showing in vitro trastuzumab resistance) responsive to the treatment.26 4-MU combined with 
trastuzumab was significantly more effective in inhibiting the growth of JIMT-1 xenografts 
than trastuzumab alone (Fig. 4A). 4-MU did not have any effect on tumour growth on its own 
(Fig. 4A), although it reduced the amount of hyaluronan in JIMT-1 tumour tissue by ~40% 
(Fig. 4B). In addition, CD44 expression was increased by 4-MU probably due to its 
decreased hyaluronan-mediated down-regulation.43 The increased CD44 level of 
trastuzumab-treated cells is probably the consequence of reduced CD44 shedding in the 
presence of trastuzumab (our unpublished observation). 4-MU downregulated ErbB2 to the 
same extent as trastuzumab. We attribute this finding to the fact that 4-MU increased the 
CD44 level of cells which was shown to correlate with increased ErbB2 internalization 
(Fig. 2). Not only did 4-MU synergize with trastuzumab in slowing tumour growth, but it also 
enhanced trastuzumab-mediated down-regulation of ErbB2 (Fig. 4B). Since we assumed that 
4-MU may unmask the trastuzumab-binding epitope on ErbB2, it was necessary to show that 
hyaluronan colocalized with the plasma membrane. By staining tumour sections for 
hyaluronan and CD44 we demonstrated that hyaluronan is present near the cell membrane, 
although it is also found in high density in areas which seem to be interstitial tissue (Fig. 5A-
C). Next, we determined the trastuzumab/ErbB2 ratio in control and trastuzumab+4-MU-
treated tumour samples and observed an obvious increase in the relative binding of 
trastuzumab to ErbB2 upon 4-MU treatment (Fig. 5D-E). Quantitative analysis of the images 
showed a shift on the trastuzumab-ErbB2 contour plot towards higher trastuzumab binding 
upon 4-MU treatment (Fig. 5F). Next, we tested the effect of in vitro 4-MU treatment on 
trastuzumab binding. JIMT-1 cells were treated with 4-MU for 48 hours, and subsequently 
labeled with AlexaFluor488-trastuzumab and AlexaFluor647-2C4. We found that 4-MU 
treatment enhanced the amount of bound trastuzumab relative to the intensity of ErbB2 (Fig. 
5G). ErbB2 was not downregulated by trastuzumab in Fig. 5G, since cells were labeled with 
trastuzumab for 30 min on ice, as opposed to Fig. 5F, where mice were treated with the 
antibody for several weeks. The trastuzumab epitope is masking sensitive 4 due to its 
membrane proximal position.44 Since the ErbB2-76.5 and 2C4 antibodies recognize an 
epitope distinct from and less masking sensitive than that of trastuzumab (our unpublished 
observation), we assumed that their intensities represented the total amount of ErbB2. The 4-
MU-induced changes in the trastuzumab/ErbB2 ratio present convincing evidence for the in 
vitro and in vivo masking effect of hyaluronan on the trastuzumab binding epitope. 
CD44 is essential for the proliferation of JIMT-1 cells in vitro. Since CD44 is 
overexpressed by JIMT-1 cells and it is involved in regulating trastuzumab-mediated ErbB2 
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internalization, we investigated whether the inhibition of CD44 expression alters the effect of 
trastuzumab in vitro. As previously shown JIMT-1 cells were resistant to trastuzumab in 
vitro,30 but their proliferation was inhibited by siRNA-mediated suppression of CD44 
expression (Fig. 6). However, no additive effect between trastuzumab and CD44 siRNA was 
detected. SKBR-3 cells responded to trastuzumab treatment, but in agreement with their low 
CD44 expression failed to show any response to siRNA-mediated suppression of CD44 
expression (Fig. 6). 
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Discussion 
CD44 is widely recognized as a key factor in lymphocyte homing and cancer progression.14 It 
has been shown to enhance the signaling potency of several growth factor receptors in 
general12 and to interact with ErbB2 in particular,5,10,11 but the involvement of the 
hyaluronan-CD44 pathway in trastuzumab resistance has not been investigated. Since the 
mechanisms behind trastuzumab resistance are largely unknown, therapeutic failure during 
prolonged treatment is practically inevitable. In JIMT-1, a cell line showing in vitro and 
partial in vivo resistance to trastuzumab,4,30 we found an overexpression of CD44. High 
expression of CD44 is a property of breast cancer stem cells45 raising the possibility that the 
JIMT-1 cell line has been initiated from a stem/progenitor cell. Immunoprecipitation, flow 
cytometric FRET and confocal microscopic experiments showed that CD44 associates with 
ErbB2. The interaction between CD44 and ErbB2 hinted that the hyaluronan-CD44 pathway 
may be involved in trastuzumab internalization and resistance. 
 siRNA-mediated suppression of CD44 expression inhibited trastuzumab 
internalization in vitro (Fig. 3). Since CD44 is known to be linked to actin6 and endocytosis 
and post-endocytic sorting are coupled to the cytoskeleton in several ways46, it is possible 
that inhibition of the expression of CD44 interferes with the endocytic process. Alternatively, 
since CD44 plays a permissive role in the activation of ErbB2,11 elimination of this 
constitutive regulator of ErbB2 may inhibit trastuzumab internalization. The role of CD44 in 
trastuzumab internalization and down-regulation was confirmed by studying the correlation 
between trastuzumab binding, ErbB2 and CD44 expressions in JIMT-1 xenografts. In control 
mice the correlation between CD44 and ErbB2 expressions was positive (Fig. 2G), which 
was converted to an inverse correlation by trastuzumab treatment (Fig. 2H). ErbB2 is down-
regulated by trastuzumab (Fig. 4B), and we assume that this process is more efficient in cells 
with high CD44 expression, therefore CD44high cells will end up being low expressers of 
ErbB2 upon trastuzumab treatment. The fact that CD44 expression correlates with 
trastuzumab-induced ErbB2 internalization in vivo agrees with our in vitro data showing 
decreased internalization of trastuzumab after knocking down CD44 expression (Fig. 3). We 
showed previously that after stopping trastuzumab injections ErbB2 expression returns to a 
level observed in untreated animals.26 While trastuzumab is cleared from the circulation 
resynthesis of ErbB2 takes place primarily in cells in which ErbB2 expression was down-
regulated, i.e. the CD44high subpopulation. Trastuzumab will probably not bind to ErbB2 
synthesized 6 weeks after stopping trastuzumab treatment, since the antibody is eliminated 
from the circulation with a half-life of ~25 days,47 and its concentration is probably lower in 
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the tumour stroma than in the circulation. Even if trastuzumab had bound to newly 
synthesized ErbB2 six weeks after stopping trastuzumab treatment, we would not have 
observed substantial cell-to-cell variation in the binding of trastuzumab to ErbB2 (Fig. 2D). 
Therefore, CD44high cells in which ErbB2 has been down-regulated will display newly 
synthesized ErbB2 without trastuzumab on their surface, i.e. their trastuzumab/ErbB2 ratio 
will be lower than that of CD44low cells in which ErbB2 has been down-regulated less 
efficiently (Fig. 2D,E). The trastuzumab/ErbB2 ratio of CD44low cells was high because they 
still displayed ErbB2 in their membrane to which trastuzumab had bound during trastuzumab 
treatment. Although the role of trastuzumab-induced ErbB2 down-regulation in the 
therapeutic action of the antibody has been questioned41,42, the debate is not yet settled. The 
finding that CD44 is involved in ErbB2 internalization and down-regulation shows that it 
influences the distribution of ErbB2 among different cellular compartments, which may alter 
the therapeutic effects of trastuzumab. Additionally, if trastuzumab is used to target ErbB2 
overexpressing cells with radioactive isotopes or chemotherapeutics, entry of the antibody-
coupled drug into the cell will be affected by the level of CD44 expression. 
 In addition to its involvement in regulating endocytosis of ErbB2, CD44 can modify 
trastuzumab-induced effects by masking ErbB2 by its bulky ligand, hyaluronan. We have 
previously described masking of ErbB2 by MUC-4, a cell surface mucin, also expressed by 
the JIMT-1 cell line.4 In this paper we established that hyaluronan also masks the 
trastuzumab binding epitope by showing that hyaluronan was present in the immediate 
vicinity of JIMT-1 cells (Fig. 5A-C), and 4-MU, an inhibitor of hyaluronan synthase,33 
substantially reduced its concentration accompanied by increased trastuzumab binding (Fig. 
4B, 5F). The enhanced expression level of CD44 in 4-MU-treated xenografts (Fig. 4B) is 
probably attributable to lower rate of hyaluronan-induced CD44 endocytosis.43 Since CD44 
seems to increase ErbB2 down-regulation (Fig. 3B), the higher CD44 level in 4-MU-treated 
samples may lead to the lower level of ErbB2 expression observed in these animals (Fig. 4B). 
Decreased concentration of hyaluronan around JIMT-1 cells resulted in increased binding of 
trastuzumab to (Fig. 5D-F) and more efficient down-regulation of ErbB2 (Fig. 4B). More 
importantly, the enhanced binding of trastuzumab to ErbB2 induced by 4-MU increased the 
efficiency of trastuzumab therapy in vivo (Fig. 4A). It has been shown previously that 
hyaluronan-cell interactions are important for cancer cell survival and metastasis.48 The fact 
that 4-MU alone did not alter the rate of JIMT-1 tumour growth compared to saline-treated 
animals suggests that either hyaluronan is not necessary for the survival of JIMT-1 cells or 
the extent of suppression of hyaluronan synthesis was not sufficient for evoking an effect on 
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tumour growth. Nevertheless, the suppression of hyaluronan synthesis induced by 4-MU 
treatment was large enough to decrease masking of ErbB2 and increase the binding and 
therapeutic effect of trastuzumab. It was reported that 4-MU inhibited the proliferation of 
keratinocytes more strongly than expected based on the level of inhibition of hyaluronan 
synthesis.49 This phenomenon was attributed to direct antiproliferative effects of 4-MU 
unrelated to hyaluronan synthesis. The fact that 4-MU as a single agent was ineffective in our 
study argues against this possibility in JIMT-1 cells. Although 4-MU specifically inhibits the 
synthesis of hyaluronan,33 we cannot rule out the possibility that the production of other 
glycosaminoglycans was also suppressed. However, the observed increase in trastuzumab 
binding after 4-MU treatment is a solid evidence for masking whatever molecules are behind 
it. 
 The extremely high overexpression of CD44 by JIMT-1 cells (~2.3 million/cell) must 
be maintained by a selective advantage conferred upon cells by CD44. Although the 
overexpression of ErbB2 is less high (0.1-0.5 million/cell3,4) it is probably a key signaling 
molecule in JIMT-1. Therefore, we wanted to investigate whether the combination of 
therapies against two overexpressed proteins results in synergism, i.e. whether suppression of 
CD44 expression will turn trastuzumab resistance into responsiveness. siRNA-mediated 
knockdown of CD44 expression decreased the proliferation of JIMT-1, but cells remained 
trastuzumab resistant (Fig. 6). The failure to induce trastuzumab sensitivity in JIMT-1 cells 
by CD44 siRNA transfection may have been caused by a possible antagonism between CD44 
siRNA and trastuzumab, since the former inhibits the internalization of the latter (Fig. 3B). 
Alternatively, the CD44-hyaluronan pathway involved in in vivo trastuzumab resistance may 
have very limited role in the in vitro resistance of JIMT-1.4 It is also possible that although 
CD44 is involved in trastuzumab internalization, it is unrelated to trastuzumab resistance due 
to the dubious role of ErbB2 internalization and downregulation in trastuzumab resistance.41 
 In conclusion, our results point to a role of CD44 in regulating trastuzumab 
internalization and masking ErbB2 by serving as an anchor of the hyaluronan meshwork. 
These findings warrant further investigation of the correlation between trastuzumab 
resistance, masking of ErbB2, CD44 and hyaluronan expressions, and a deeper look at how 
CD44-expressing breast cancer stem cells are affected by trastuzumab therapy. 
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Figure 1 CD44 is overexpressed in JIMT-1 cells and interacts with ErbB2 
A. JIMT-1 (grey dashed line) and SKBR-3 (black dashed line) cells were labeled with 
AlexaFluor488-Hermes-3 antibody against CD44, and the fluorescence intensity was 
measured by flow cytometry. Unlabeled JIMT-1 (grey continuous line) and SKBR-3 (black 
continuous line) cells were used as a negative control. 
B. JIMT-1 and SKBR-3 cells were labeled with Cy3-2C4 (against ErbB2) and Cy5-Hermes-3 
(against CD44), and the FRET efficiency was measured by flow cytometry (black bars) and 
the cross-correlation coefficient by confocal microscopy (grey bars). Cells labeled with two 
non-competing antibodies against ErbB2 (Cy3-trastuzumab, Cy5-2C4) were used as a 
positive control for both FRET and cross-correlation measurements. Error bars indicate the 
standard error of the mean. 
C. JIMT-1 cells were labeled with AlexaFluor488-2C4 and AlexaFluor647-Hermes-3 against 
ErbB2 and CD44, respectively. The red and green channels correspond to ErbB2 and CD44, 
respectively. The yellow color represents overlap between the two fluorescence channels. 
Quantitative evaluation of colocalization is shown in part B. 
D. Left panel: JIMT-1 cell lysate was immunoprecipitated with Hermes-3 (against CD44), 
and the membrane was blotted with Hermes-3 and OP15 (against ErbB2). Middle and right 
panels: JIMT-1 cells were stimulated with 100 μg/ml hyaluronan decasaccharide (HA10) or 
large molecular weight hyaluronan (HA-LMW) for 30 min at 37 oC. ErbB2 (middle panel) 
and ErbB1 (right panel) were immunoprecipitated with OP15 and F4, respectively. The 
membranes were probed with OP15, F4 and PY99 to detect ErbB2, ErbB1 and 
phosphotyrosine, respectively. 
 
Figure 2 CD44 enhances trastuzumab internalization in JIMT-1 xenografts 
A-E. Immunofluorescent staining of JIMT-1 xenografts samples was carried out six weeks 
after finishing trastuzumab treatment. Sections were triple-stained with AlexaFluor488-
ErbB2-76.5, Cy3-anti-human IgG (recognizing trastuzumab) and AlexaFluor647-Hermes-3 
(against CD44). The cell membrane identified by a manually-seeded watershed algorithm is 
shown in red (A). Dual color images show the correlation of signals (B: red – ErbB2, green – 
trastuzumab; C: red – CD44, green – trastuzumab). Gate 1 and 2 identify regions in the 
trastuzumab-ErbB2 contour plot (D) corresponding to pixels with high and low trastuzumab-
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ErbB2 ratios, respectively. The CD44 intensity distributions corresponding to gate 1 and 2 
are shown in part E. 
F. Mice xenografted with JIMT-1 tumours were treated by trastuzumab for 15 weeks and 
tumour samples were stained with AlexaFluor488-ErbB2-76.5 and Cy3-anti-human IgG 
recognizing trastuzumab. The contour plot shows a much stronger correlation between the 
ErbB2 and trastuzumab signals compared to that observed in part D. 
G-I. Mice injected with JIMT-1 cells were treated with saline (G) or trastuzumab (H) for 15 
weeks. In another group mice were sacrificed 6 weeks after a 9-week long trastuzumab 
treatment was stopped (I), and the correlation between CD44 and ErbB2 expression levels 
was analyzed in the three samples. 
 
Figure 3 siRNA-mediated suppression of CD44 expression inhibits trastuzumab 
internalization 
A. JIMT-1 cells were transfected with an irrelevant siRNA against GFP (black), CD44 
siRNA-4 (white) and CD44 siRNA-5 (grey). The bars show the expression levels of CD44 
and an irrelevant protein, MHC-I, calculated from flow cytometric histograms analyzed 48 
hours after transfection. 
B. Internalization of trastuzumab was measured in mock-transfected cells (●), cells 
transfected with GFP siRNA (○), CD44 siRNA-4 (▼) or CD44 siRNA-5 (◊). The fraction of 
internalized trastuzumab (100%=amount of trastuzumab bound to the cell surface at 0 min) is 
plotted as a function of the duration of trastuzumab treatment. The 30 min values of both 
CD44 siRNA-transfected samples were statistically significantly different from the GFP 
siRNA-transfected one (Student’s t test, p<0.05). Error bars indicate the standard error of the 
mean. 
 
Figure 4 4-methylumbelliferone acts synergistically with trastuzumab in inhibiting 
tumour growth and down-regulating ErbB2 expression 
A. Mice were xenografted with JIMT-1 cells, and treated with saline (●), trastuzumab (○), 4-
methylumbelliferone (▼) or trastuzumab+4-methylumbelliferone (◊). 4-methylumbelliferone 
treatment was carried out daily. At the times of weekly saline and trastuzumab treatments 
indicated by the arrows the size of tumours was measured, and it is displayed as function of 
time. 
B. Tissue sections were triple-labeled with biotin-HABC and fluorescein-avidin to visualize 
hyaluronan, and antibodies against CD44 and ErbB2. The cell membrane of JIMT-1 cells was 
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identified by the manually-seeded watershed algorithm. The mean (±standard error of the 
mean) expression levels of hyaluronan, CD44 and ErbB2 measured around the cell 
membrane in trastuzumab (white), 4-methylumbelliferone (left-hatched) and trastuzumab+4-
methylumbelliferone (grey) treated animals were normalized to the saline-treated xenograft 
samples (black). The means were calculated from 6 images taken of tissue sections of 3 
animals. 
 
Figure 5 Inhibition of hyaluronan synthase increases binding of trastuzumab to ErbB2 
A-C. JIMT-1 tumour samples of saline-treated animals were stained for hyaluronan with 
biotin-HABC (A) and for CD44 (B). The color composite image shows the overlap of the 
distribution of the hyaluronan (green) and CD44 (red) signals. 
D-F. Tumour sections of mice treated with trastuzumab (D) or trastuzumab+4-
methylumbelliferone (E) were stained with anti-human IgG (recognizing trastuzumab, green) 
and ErbB2-76.5 (red) antibodies. The contour plot (F) shows increased binding of 
trastuzumab to ErbB2 in samples taken from the trastuzumab+4-methylumbelliferone-treated 
animals (red contours) compared to the trastuzumab-treated ones (black contours). The axes 
of the contour plot show fluorescence intensity values of trastuzumab and ErbB2-76.5 
antibodies recorded in membrane pixels which were identified by manually-seeded watershed 
segmentation. 
G. Cultured JIMT-1 cells were treated with 4-methylumbelliferone for 2 days. Both control 
(black contours) and 4-methylumbelliferone-treated (red contours) cells were stained with 
AlexaFluor488-trastuzumab and AlexaFluor647-2C4. The latter antibody measured the 
amount of ErbB2. 
 
Figure 6 RNA interference-mediated suppression of CD44 expression inhibits 
proliferation of JIMT-1 cells 
An equal number of mock-transfected cells (white bars) and cells transfected with GFP 
siRNA (black bars) or CD44 siRNA-4 (grey bars) were seeded into 6-well plates 24 hours 
after transfection, and cultured in the absence (–trast) or presence (+trast) of 20 μg/ml 
trastuzumab for 72 hours. Cell numbers are normalized to the number found in mock-
transfected, trastuzumab-untreated cells 72 hours after transfection. 
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